I have wanted to interview Dr Kirk for this series in
Progress in Transplantation for a long time. In the past he told me he did not think he fit into this category of leaders and legends, but after 5 years, he finally agreed. I met Dr Kirk in his office at Duke University in Durham North Carolina, where he is the Chairman of the Department of Surgery and Surgeon-in-Chief for the Duke Health System. As I walked to his office, I walked by a door with an American Journal of Transplantation sign and was reminded of one of his prestigious leadership and legendary roles: Editor of the American Journal of Transplantation.
Dr Kirk continues to participate in kidney transplant surgery whenever possible. And he loves teaching. That was evident to me more than 15 years ago when I worked with him at the National Institutes of Health (NIH), implementing his research protocols on co-stimulatory pathways. Rounding with Dr Kirk was like being in a classroom, studying the complexities of the immune system.
Career Path
When I asked Dr Kirk if he always wanted to be a physician, he grinned and said "No, I wanted to be a tuba player!" After graduating from high school in Virginia Beach, Virginia, Dr Kirk went to Boston University to study music. As a high school student, he had played with the Boston Symphony at Tanglewood, the famous outdoor music theater, and he had moved to Boston to perform and study tuba. In the early 1980s, as Dr Kirk was making decisions about his career, he heard news stories about advances in the field of transplantation. Every time a transplant was successful, it was in the news, and new drugs were promising to make transplants even more successful. As he listened to these successes and advances, he knew he wanted to be on the forefront of scientific discoveries. And so one day, and he describes this as an epiphany, he told his family he had decided to become a transplant surgeon. Dr Kirk began the process of becoming a physician by enrolling in Old Dominion University and taking all of the science and mathematics requirements of a Biology degree in 2 years. He graduated Summa Cum Laude with a Bachelor's Degree in Biology from Old Dominion University. His fiancé Robin was a nurse who had completed a clinical rotation at Duke University hospital. She spoke highly of her experiences at Duke, which encouraged Dr Kirk to apply to the medical school at Duke University. As we talked about his decision to attend medical school, Dr Kirk was quick to tell me that he had no idea what he was doing. His father also knew that he had no idea what he was doing. He advised Dr Kirk to wear a tuba tie tack to an interview at Duke and told him not to button his jacket. Dr Kirk followed his father's instructions and, interestingly, the interview somehow focused on the tuba tie tack. He anticipated questions about science and his goals for becoming a doctor, but the interview focused on music, his experiences at Tanglewood, and playing the tuba. In 1983 he entered Duke University School of Medicine and graduated in 1987.
Introduction to the Immune System
In his first year of medical school, Dr Kirk was paired with a trauma surgeon, Dr Greg Georgiade. One day he watched Dr Georgiade repair an aorta and then slip away to participate in a triathlon. Dr Kirk thought, "I want to be him!"
Also during his first year, Dr Kirk met Dr Randy Bollinger, an abdominal transplant surgeon. Dr Bollinger recognized the passion and potential in the young medical student and mentored him and gave him guidance to become a transplant surgeon. Dr Kirk worked in Dr Bollinger's laboratory and was given a project to develop a surgical procedure for doing a bowel transplant using rats. Dr Kirk was a third-year medical student at this time. Dr Bollinger had a PhD in Immunology and much of Dr Kirk's work focused on the immune system. This work piqued his interest and he began taking courses in immunology.
After medical school, Dr Kirk remained at Duke for his residency. He developed great relationships with immunologists such as Olivera Finn, PhD. This new interest prompted him to study for a PhD in Immunology. He had to find a way to pay for these continuous
Editorial
Courage and character, leaders and legends: an interview with Allan D. Kirk 
Contacts and Collaboration in the Navy
To help pay for his medical college education, Dr Kirk had joined the Navy. He was deferred from the Navy to study for his PhD in Immunology at Duke. A few years later he was again deferred from the Navy to do a fellowship in transplantation. The Navy was interested in immunology and transplantation as part of studies in bone marrow transplant. In his last year of residency, Dr Kirk traveled to Washington, DC, for meetings at Walter Reed Army Medical Center. Out of pure curiosity he looked through the phone book and found a listing for the Naval Medical Research Institute. He was able to set up a meeting with Dr Carl June, an oncologist who had discovered CD28 and was doing research in T cell therapy.
On his way to meet Dr June, Dr Kirk got lost in the long hallways. He saw a door with a Duke University emblem on it and behind this door he met Dr David Harlan, a graduate of Duke University, who worked with Dr June. They talked about the work Dr Harlan was doing with Dr June and discussed how they could collaborate. Ironically, Drs Harlan and June needed a surgeon to help with some of their studies. It was 1995 and Dr Kirk was going to the University of Wisconsin for a 2-year fellowship in transplant surgery. Dr Kirk suggested a collaboration with the researchers from the University of Wisconsin. This collaboration developed into studies that led to many new discoveries about manipulating the immune system and developing drugs that could be applied to transplanted organs as well as to the treatment of diseases such as cancer.
Dr Kirk speaks of his career as if he had good fortune in many cases. However, he also recognizes that all of the connections he made were with professionals who wanted to make significant strides in medicine. As the collaboration began with the University of Wisconsin, Drs June and Harlan were true partners in the relationship and did not try to claim ownership of the studies. When Dr Kirk approached Dr Hans Sollinger, Chief of Transplantation at the University of Wisconsin, he encouraged him to do all the research he wanted. He worked with Dr Stuart Knechtle, a transplant surgeon at the University, in implementing research on co-stimulatory pathways. Their work caught the attention of Dr Dennis Bernard Amos, a noted immunologist at Duke University who urged the newly formed group of researchers to publish their work. This resulted in a paper published in the Proceeds of the National Academy of Sciences 2 in 1997 and was the first paper to describe the potential of co-stimulatory pathways to increase the survival of transplanted grafts in primates.
Applying Co-Stimulation Research to Humans
The courage, character, and leadership of this young physician were becoming quite evident to many, including the Director of NIH, Dr Harold Varmus. Dr Varmus invited Dr Kirk to a meeting to determine how his research could be implemented at the NIH. Dr Kirk was somewhat astounded when he found out who he was meeting with. He described them as "rocket science guys." Here was a young physician who had set out to be a tuba player and was now sitting down with some of the most brilliant minds in medicine. Two important actions resulted from this meeting: an invitation for Drs Kirk and Harlan to begin tolerance studies at the NIH and establishment of the immune tolerance network that was led by Dr Jeffrey Bluestone.
As Drs Kirk and Harlan began the plans for tolerance studies at the NIH, Dr Kirk knew they were embarking on a significant and revolutionary pathway for transplantation. They applied the principles of costimulation from primates to humans! The research was compelling and had the attention of many who sought to improve the outcomes of solid-organ transplantation. Drugs were used in humans for the first time in the hopes of delaying onset of acute allograft renal rejection. The use of induction therapy with monoclonal antibodies was applied to kidney transplant. Patients in need of a kidney transplant sought participation in the study with hopes that minimal, if any, immunosuppression would be needed. Participating in the original trials required a living donor. This allowed researchers to administer induction therapy with the goal of depleting lymphocytes in an attempt to produce tolerance to the new allograft. The drugs had worked well in non-human primates, so why would it not work in humans? 3 There were a few successes and a few protocols that proved not to be effective in achieving the goal of delaying allograft rejection. However, much was learned from these trials and new medications resulted from the lessons learned. I had the opportunity to work with Dr Kirk at the NIH in applying the co-stimulatory trials to humans.
A Creative and Brilliant Mind
In a recent reunion of transplant fellows at the University of Wisconsin, Dr Kirk compared building a career to winning at Tetris. Tetris is a video game with 4 shapes that must be made to fit into a straight line. There are long, angled, square, and L-shaped pieces, and all of them are made with 4 squares. The object of the game is to line the shapes up into a row, but you cannot choose what shapes you have. You get points for making a row with the shapes. Dr Kirk compares this game to building a career. He uses 4 areas of career growth as the comparison: Clinical Practice, Laboratory Investigation, Education, and Administration. To succeed, especially in transplantation, you need to develop all 4 areas, but he wisely notes that you have to change to make them all fit. Sometimes it feels impossible to line all 4 areas up just as it seems impossible in Tetris. In a career, success may line up more easily vertically by mastering one area at a time in an upward fashion. Dr Kirk has made career building look easy with his numerous successes in each of the 4 areas.
Dr Kirk is a very thoughtful, insightful, and pragmatic individual. He knows that just because we think something should work, it does not mean it will. 4 He understands that tolerance is a "current diagnosis and not a permanent one" because of the complexity of the immune system. 1 His ability to bring things to a level most can understand is enviable. Examples are evident in his presentations and writings. My personal favorite is his paper on co-stimulation and tolerance, 5 which is a perfect example of his creativity and his brilliant mind. He stimulates our scientific community with his innovative thoughts, his science, his publications, and his endless quest to contribute to our understanding of the immune system. It is that courage, character, and leadership that make him legendary.
